NASDAQ:ZFGN Zafgen (ZFGN) Stock Price, News & Analysis → The 'Smart Money' Is Ready for May 1st Are You? (From Stansberry Research) (Ad) Free ZFGN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$6.32▼$6.5050-Day Range$0.99▼$25.0652-Week Range$0.62▼$2.76Volume222,439 shsAverage Volume360,199 shsMarket Capitalization$242.06 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get Zafgen alerts: Email Address Ad Chaikin AnalyticsWall Street Legend Issues New NVDA WarningLegendary Stockpicker: "Buy this A.I. stock NOW" His award-winning system pinpointed NVDA and META before both stocks doubled. Now it's flashing "BUY" on this under-the-radar A.I. stock.Click here for the stock details About Zafgen Stock (NASDAQ:ZFGN)Zafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. It also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts.Read More Ad Chaikin AnalyticsWall Street Legend Issues New NVDA WarningLegendary Stockpicker: "Buy this A.I. stock NOW" His award-winning system pinpointed NVDA and META before both stocks doubled. Now it's flashing "BUY" on this under-the-radar A.I. stock.Click here for the stock details ZFGN Stock News HeadlinesApril 9, 2023 | marketwatch.comGlobal Weight Loss Therapeutics Professional Market 2023 (Exclusive Report) | Future Work Trend by 2030February 26, 2023 | thestreet.comZafgen (ZFGN) Stock Skyrockets on Positive Obesity Drug ResultsApril 25, 2024 | Stansberry Research (Ad)See this before next week's Fed meetingSee this before next week's Fed Meeting Doc Eifrig just released a new video detailing "the perilous moment Americans are in right now." Angry voters, mounting government debt, and blood in the streets… But he's got a way out – a unique way to come out on top no matter who wins this presidential election. (Last time we shared this, it led to a 995% gain.) January 13, 2023 | thestreet.comZafgen (ZFGN) Stock Surges on Positive Obesity Drug TrialNovember 8, 2022 | bbc.co.ukFood and drink in a castleSeptember 30, 2022 | seekingalpha.comLRMR Larimar Therapeutics, Inc.September 14, 2022 | streetinsider.comForm 424B5 Larimar Therapeutics, - StreetInsider.comApril 12, 2022 | streetinsider.comForm DEF 14A Larimar Therapeutics, For: May 10 - StreetInsider.comApril 25, 2024 | Stansberry Research (Ad)See this before next week's Fed meetingSee this before next week's Fed Meeting Doc Eifrig just released a new video detailing "the perilous moment Americans are in right now." Angry voters, mounting government debt, and blood in the streets… But he's got a way out – a unique way to come out on top no matter who wins this presidential election. (Last time we shared this, it led to a 995% gain.) March 25, 2022 | marketscreener.comLARIMAR THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) - Marketscreener.comNovember 12, 2021 | marketscreener.comLARIMAR THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - marketscreener.comNovember 12, 2021 | streetinsider.comLarimar Therapeutics Reports Third Quarter 2021 Operating and Financial Results - StreetInsider.comNovember 12, 2021 | globenewswire.comLarimar Therapeutics Reports Third Quarter 2021 Operating - GlobeNewswireOctober 22, 2021 | finance.yahoo.comAnti-Obesity Therapeutics Market Research Report by Mechanism of Action, by Drug Type, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19 - Yahoo FinanceOctober 20, 2021 | benzinga.comAnti-Obesity Therapeutics Market Research Report by Mechanism of Action, by Drug Type, by Region - Global - BenzingaSeptember 21, 2021 | streetinsider.comFauna Bio Raises $9 Million to Expand Comparative Genomics Platform for Novel Target Discovery - StreetInsider.comSeptember 21, 2021 | prnewswire.comFauna Bio Raises $9 Million to Expand Comparative Genomics Platform for Novel Target Discovery - PRNewswireAugust 2, 2021 | seekingalpha.comVividion Therapeutics Begins U.S. IPO Effort - Seeking AlphaSee More Headlines Receive ZFGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zafgen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2020Today4/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:ZFGN CUSIPN/A CIK1374690 Webwww.zafgen.com Phone617-622-4003FaxN/AEmployees38Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-45,410,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-51.34% Return on Assets-34.55% Debt Debt-to-Equity Ratio0.26 Current Ratio6.56 Quick Ratio6.56 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.35 per share Price / Book4.79Miscellaneous Outstanding Shares37,470,000Free FloatN/AMarket Cap$242.06 million OptionableNot Optionable Beta0.27 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Jeffrey S. Hatfield (Age 61)CEO & Director Ms. Patricia L. Allen (Age 57)Chief Financial Officer Dr. Dennis D. Kim M.D. (Age 49)MBA, Chief Medical Officer Dr. James E. Vath (Age 58)Head of Discovery & Devel. Mr. Brian P. McVeigh (Age 46)Chief Bus. Officer Key Competitors23andMeNASDAQ:ME2seventy bioNASDAQ:TSVTVerastemNASDAQ:VSTMAC ImmuneNASDAQ:ACIUPuma BiotechnologyNASDAQ:PBYIView All Competitors ZFGN Stock Analysis - Frequently Asked Questions How were Zafgen's earnings last quarter? Zafgen Inc (NASDAQ:ZFGN) announced its quarterly earnings results on Thursday, March, 5th. The biopharmaceutical company reported ($0.19) EPS for the quarter, meeting the consensus estimate of ($0.19). What other stocks do shareholders of Zafgen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zafgen investors own include SCYNEXIS (SCYX), Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), Energy Transfer (ET), TG Therapeutics (TGTX), BlackRock (BLK), Fate Therapeutics (FATE), Pfizer (PFE), Spectrum Pharmaceuticals (SPPI) and Esperion Therapeutics (ESPR). This page (NASDAQ:ZFGN) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap Profits“The Biggest Bubble of All Time” – Here’s What to Do.Chaikin Analyticstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zafgen Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
